Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization
about
Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosisToward Optimization of the Linker Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis InhibitorsToward Optimization of the Second Aryl Substructure Common to Transthyretin Amyloidogenesis Inhibitors Using Biochemical and Structural Studies †A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and CytotoxicityChemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasmaTrapping of palindromic ligands within native transthyretin prevents amyloid formationAromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent ConjugateTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeX-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitorsThe flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic responseInhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel.A stilbene that binds selectively to transthyretin in cells and remains dark until it undergoes a chemoselective reaction to create a bright blue fluorescent conjugate.Binding site asymmetry in human transthyretin: insights from a joint neutron and X-ray crystallographic analysis using perdeuterated proteinA competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.Regioselective copper-catalyzed amination of bromobenzoic acids using aliphatic and aromatic amines.Regioselective copper-catalyzed amination of chlorobenzoic acids: synthesis and solid-state structures of N-aryl anthranilic acid derivativesRegioselective Copper-catalyzed C-N and C-S Bond Formation using Amines, Thiols and Halobenzoic AcidsThe transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.Gelsolin amyloidosis: genetics, biochemistry, pathology and possible strategies for therapeutic intervention.Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.Current and future treatment of amyloid diseases.Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design.Chaperonin-Based Biolayer Interferometry To Assess the Kinetic Stability of Metastable, Aggregation-Prone ProteinsDevelopment of dimeric modulators for anti-apoptotic Bcl-2 proteins.Partitioning conformational intermediates between competing refolding and aggregation pathways: insights into transthyretin amyloid disease.The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors.Investigating the effects of mutations on protein aggregation in the cell.Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis.Modulators of 14-3-3 Protein-Protein Interactions.CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.Stabilization of protein-protein interactions in drug discovery.Multivalent helix mimetics for PPI-inhibition.CHF5074 (CSP-1103) stabilizes human transthyretin in mice humanized at the transthyretin and retinol-binding protein loci.Understanding and Ameliorating the TTR Amyloidoses
P2860
Q27004511-77C58DBC-2A80-43E6-9600-E1DE163C8776Q27652272-41811C24-A78B-4B47-B3BD-2FA34BEF5614Q27653350-AEB67CAB-C878-44B8-8B4F-E8FA98FEB69BQ27653642-17571B6A-04D4-493B-9CAB-954C5D5A154AQ27658823-3F71326C-A1C0-4160-AC02-5F0DF7F26050Q27659009-A87D321C-FA44-4F7C-9FA6-D1373A5159C6Q27665687-8794A28A-6EA3-4422-97E7-EECEDC40226DQ27675997-33066D48-F89C-4559-90C4-62E82A20A0EAQ27679360-CB2343DC-FA80-4314-BF4E-E85487E0DC63Q27701718-3F32CF1F-E67D-4899-A805-7B0E64D77E71Q28547541-686E3146-CED1-466D-ADBF-DF3BA360B5A4Q33671132-A466F658-265C-4362-B68C-C6DC0C7C5E06Q34300151-EC7FA7C4-5477-49A6-B5E2-45D44ADE4FFCQ34473216-5F03F4FC-FC28-4A50-9B9C-47B16F71570AQ34576022-A028531F-758F-459E-9D40-A72B712DDDE1Q34581917-9626B454-CB4A-4C11-B2EE-2CDEE72A7F03Q36866009-416F5DD3-72D3-4D04-90D7-59C0A7A2E8CAQ36871484-B0487A08-B851-45E5-A076-3DACF41CFAD3Q37035742-FD02A298-29EF-4AA2-8C64-2DA164B52E8AQ37975816-E57CFE1B-1159-487F-B411-B053A8FB65BDQ37987587-84ECEC91-D3B0-41C0-B86D-883B4C5C74E9Q38720600-1B794188-7493-4542-BD31-B5CE536367E7Q38831388-8EE1F97A-5644-42E7-9062-E57ECF4F40EDQ39254356-FA6B841A-7AA1-4A8C-BAFC-E261A48B9BA7Q41109894-9155454E-BC13-4F71-8A9E-CD8E97D53063Q41953261-5EDC779B-F8EE-44FA-AF89-76ACA7BBDD09Q42173801-B44F3D82-C9E5-4F2A-931E-549E24D3536AQ45094644-3D606737-838C-4F25-A114-4FB67D290B92Q45195856-6F3E7A47-193C-4FD7-AE84-94AD7CB95773Q47404960-8CB03E62-DBC2-4F9A-8616-80026FD61455Q47610334-FC0A6A81-3007-4A7A-9248-2816D17B247BQ47924309-9AFE5636-427F-4ECB-B661-69DB4D6D2C93Q47938743-73ADFE38-9723-4482-A2DC-8B57473CA501Q51034269-50FBF801-4044-4CD1-8AC8-D91F8CFF6EC5Q51654182-8CC55970-8532-45CE-98CB-F79D4D958C63Q57445076-B6A2FF54-3A48-4372-B7A0-29E74E60F4DC
P2860
Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization
description
2003 nî lūn-bûn
@nan
2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Synthesis and characterization ...... transthyretin tetramerization
@ast
Synthesis and characterization ...... transthyretin tetramerization
@en
Synthesis and characterization ...... transthyretin tetramerization
@nl
type
label
Synthesis and characterization ...... transthyretin tetramerization
@ast
Synthesis and characterization ...... transthyretin tetramerization
@en
Synthesis and characterization ...... transthyretin tetramerization
@nl
prefLabel
Synthesis and characterization ...... transthyretin tetramerization
@ast
Synthesis and characterization ...... transthyretin tetramerization
@en
Synthesis and characterization ...... transthyretin tetramerization
@nl
P2093
P356
P1476
Synthesis and characterization ...... transthyretin tetramerization
@en
P2093
James C Sacchettini
Nora S Green
Satheesh K Palaninathan
P304
P356
10.1021/JA030294Z
P407
P577
2003-11-05T00:00:00Z